The Association of Accessible Medicines (AAM) has released the report ‘A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain’ that offers advice on how the Federal Government could create capacity to manufacture critical medicines in the USA and allied countries (1).
Suggestions include the government’s direct engagement with pharma companies to identify opportunities for investment; the FDA’s improved engagement with manufacturers, as well as the agency developing more efficient regulatory processes for the review and approval of pharmaceutical products; and the scale-up of the US Department of Health and Human Services to expand the nation’s supply chain.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
References
- AAM, “A Blueprint for Enhancing the Security of the US Pharmaceutical Supply Chain”, (2020). Available at: https://bit.ly/3d5Rj1t
